title: The treatment of autism with low-dose phenytoin: a case report.
abstract: BACKGROUND
  The drug treatment of autism spectrum disorders is often poorly tolerated and has traditionally targeted associated conditions (such as inattention or irritability) that frequently coexist, with limited benefit for the core social deficits. Here, I describe the novel use of a low dose of the anti-epileptic phenytoin to enhance social functioning in a patient with an autism spectrum disorder.
  
  
  METHODS
  I present the case of a 19-year-old Caucasian man with autism spectrum disorder treated with stimulant medication since early childhood. He experienced long-standing difficulties in establishing and maintaining relationships and reading social cues, and was socially isolated. Within 10 minutes of a single sublingual low dose of phenytoin there was an immediate observable improvement in his eye contact and integration of both verbal and non-verbal communication. This enhanced social functioning associated with his adherence to the low-dose phenytoin therapy was maintained for over 18 months of follow-up. These clinical observations were supported by ratings using the Autism-Spectrum Quotient and the Depression, Anxiety and Stress Scales, recorded pre-treatment and after seven months on 5mg phenytoin.
  
  
  CONCLUSIONS
  This case report provides the first potential evidence that a low dose of phenytoin, a widely used and well tolerated anti-epileptic medication, may be capable of modifying the core social cognitive deficits associated with autism spectrum disorders. While acknowledging this is a single case study, the lack of availability of safe and effective treatments to address the important core deficits associated with autism spectrum disorders makes this case noteworthy.
authors.affiliation: PO Box 680, Maroochydore 4558, QLD, Australia. philb@gosforthclinic.com.au.
authors.forename: Philip D
authors.initials: PD
authors.lastname: Bird
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D001321:Autistic Disorder / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects*; D012919:Social Behavior; D066107:Social Skills; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D010672:Phenytoin